Your browser doesn't support javascript.
In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
Singh, Ameeta.
  • Singh A; University of Alberta, Edmonton, Alberta, Canada (A.S.).
Ann Intern Med ; 174(1): JC3, 2021 01.
Article in English | MEDLINE | ID: covidwho-1518748

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Ritonavir / Lopinavir / COVID-19 Drug Treatment / Hospitalization Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Ann Intern Med Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Ritonavir / Lopinavir / COVID-19 Drug Treatment / Hospitalization Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Ann Intern Med Year: 2021 Document Type: Article